{
  "id": 3288191,
  "title": "BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA",
  "url": "https://urgent.news/2026/08/25/beone-medicines-announces-u-s-fda-approval-for-tevimbra-based-regimen",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-25T14:43:03.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-announces-u-s-fda-approval-for-tevimbra-based-regimen-for-first-line-her2-gea"
  },
  "original_language": "en",
  "account": null,
  "summary": "TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become standard of care in this difficult-to-treat disease. SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}